TY - JOUR
T1 - Wide Area Transepithelial Sampling with Computer Assisted Analysis (WATS3D) to detect High Grade Dysplasia and Cancer in Barrett's esophagus
T2 - A Multi-Center, Randomized Study
AU - van Munster, Sanne
AU - Leclercq, Philippe
AU - Haidry, Rehan
AU - Messmann, Helmut
AU - Probst, Andreas
AU - Ragunath, Krish
AU - Bhandari, Pradeep
AU - Repici, Alessandro
AU - Munoz-Navas, Miguel
AU - Seewald, Stefan
AU - Lemmers, Arnaud
AU - Fernández-Esparrach, Glòria
AU - Pech, Oliver
AU - Schoon, Erik J.
AU - Kariv, Revital
AU - Neuhaus, Horst
AU - Weusten, Bas L. A. M.
AU - Siersema, Peter D.
AU - Correale, Loredana
AU - Meijer, Sybren L.
AU - de Hertogh, Gert
AU - Bergman, Jacques Jghm
AU - Hassan, Cesare
AU - Bisschops, Raf
N1 - Funding Information: The study was financially supported by CDx diagnostics, Inc. CDx diagnostics supported the study personnel cost and provided study brushes. The sponsor had no role in the design and conduct of the study; collection; management; analysis; and interpretation of the data. The sponsor was provided with a draft prior to submission and did submit feedback to the authors. RB has received consultancy fees from CDx Diagnostics. GH’s employer University of Leuven receives payments for involvement as central pathology reader in the study. RK is supported by grant from Pfizer. PDS is supported by a grant from Pentax, MicroTech, The Enose company and Motus GI. KR received consultancy fees from CDX diagnostics. The other authors declared to have no disclosures. Publisher Copyright: © 2022 Georg Thieme Verlag. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Background and aims Current surveillance for Barrett's esophagus (BE), consisting of 4-quadrant random forceps biopsy (FB), has an inherent risk of sampling error. Wide-Area Transepithelial Sampling (WATS) may increase detection of high-grade dysplasia (HGD) and adenocarcinoma (EAC). In this multicenter, randomized trial, we aimed to evaluate WATS as a substitute for FB. Methods Patients with known BE and a recent history of dysplasia, without visible lesions, at 17 hospitals were randomized to receive either WATS followed by FB or vice-versa. All WATs samples were examined, with computer assistance, by at least two experienced pathologists at the CDx Laboratory. Similarly, all FBs were examined by two expert pathologists. The primary endpoint was concordance/disconcordance for detection of HGD/EAC between both techniques. Results 172 patients were included. Of these, 21 had HGD/EAC detected with both modalities, 18 other had HGD/EAC detected by WATS, but missed with FB and 12 were detected by FB but missed by WATS. The detection rate of HGD/EAC did not differ between WATS and FB (p=0.36). Utilizing WATS as an adjunct to FB significantly increased detection of HGD/EAC vs FB alone (absolute increase 10% [95%-CI: 6-16%]). Mean procedural times in minutes for FB alone, WATS alone, and the combination were 6.6 (95% CI:5.9-7.1), 4.9 (95% CI:4.1-5.4), and 11.2 (95%-CI:10.5-14.0) respectively. Conclusions Although the combination of WATS and FB increases dysplasia detection in a population of BE patients enriched for dysplasia, we did not find a statistically significant difference between WATS and FB for detection of HGD/EAC as single modality.
AB - Background and aims Current surveillance for Barrett's esophagus (BE), consisting of 4-quadrant random forceps biopsy (FB), has an inherent risk of sampling error. Wide-Area Transepithelial Sampling (WATS) may increase detection of high-grade dysplasia (HGD) and adenocarcinoma (EAC). In this multicenter, randomized trial, we aimed to evaluate WATS as a substitute for FB. Methods Patients with known BE and a recent history of dysplasia, without visible lesions, at 17 hospitals were randomized to receive either WATS followed by FB or vice-versa. All WATs samples were examined, with computer assistance, by at least two experienced pathologists at the CDx Laboratory. Similarly, all FBs were examined by two expert pathologists. The primary endpoint was concordance/disconcordance for detection of HGD/EAC between both techniques. Results 172 patients were included. Of these, 21 had HGD/EAC detected with both modalities, 18 other had HGD/EAC detected by WATS, but missed with FB and 12 were detected by FB but missed by WATS. The detection rate of HGD/EAC did not differ between WATS and FB (p=0.36). Utilizing WATS as an adjunct to FB significantly increased detection of HGD/EAC vs FB alone (absolute increase 10% [95%-CI: 6-16%]). Mean procedural times in minutes for FB alone, WATS alone, and the combination were 6.6 (95% CI:5.9-7.1), 4.9 (95% CI:4.1-5.4), and 11.2 (95%-CI:10.5-14.0) respectively. Conclusions Although the combination of WATS and FB increases dysplasia detection in a population of BE patients enriched for dysplasia, we did not find a statistically significant difference between WATS and FB for detection of HGD/EAC as single modality.
UR - http://www.scopus.com/inward/record.url?scp=85140258736&partnerID=8YFLogxK
U2 - https://doi.org/10.1055/a-1949-9542
DO - https://doi.org/10.1055/a-1949-9542
M3 - Article
C2 - 36150646
SN - 0013-726X
JO - Endoscopy
JF - Endoscopy
ER -